Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus NivolumabYusuke Yano, Haruhito Azuma, Kiyoshi Takahara et al.|Cancers|2022Cited by 21
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial CarcinomaTaizo Uchimoto, Haruhito Azuma, Takuya Matsuda et al.|Targeted Oncology|2024Cited by 12
Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinomaTaizo Uchimoto, Haruhito Azuma, Tatsuo Fukushima et al.|British Journal of Urology|2022Cited by 10
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint InhibitorsTaizo Uchimoto, Haruhito Azuma, Shuya Tsuchida et al.|Targeted Oncology|2024Cited by 9
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective StudyTakuhisa Nukaya, Ryoichi Shiroki, Kiyoshi Takahara et al.|Clinical Genitourinary Cancer|2023Cited by 8